Advances that are changing the diagnosis and treatment of malignant bone tumors
Authors:
- 1 January 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 17 (1) , 79-85
Abstract
Several neoplastic conditions may affect bone. These include primary bone tumors as well as metastatic disease from distant primary sites. Often, these entities produce symptoms that may be difficult to distinguish from those of various rheumatologic entities. The purpose of this review is to discuss recent developments in orthopedic oncology, with special attention given to advances that are changing the diagnosis and treatment of bone sarcomas and carcinomas metastatic to bone. Much effort in the field of musculoskeletal oncology has been dedicated to the elucidation of the molecular mechanisms underlying bone sarcomas, especially in the case of osteogenic sarcoma and Ewing family tumor. Telomere maintenance mechanisms are emerging as potential targets for anticancer therapy. The most exciting advances have been in the development of novel treatments for cancers affecting bone. The anticancer effects of bisphosphonates, cyclooxygenase-2 inhibitors, and statins may expand their indications to the treatment of primary bone tumors. Finally, new expandable implants have been developed for the treatment of bone tumors in growing children. These devices may help solve some of the problems encountered with reconstruction of the growing skeleton. Recent discoveries in the molecular mechanisms of bone sarcomas may help to elucidate the pathogenesis of these rare diseases. This, combined with the recent findings of the anticancer effects of bisphosphonates, cyclooxygenase-2 inhibitors, and statins, may lead to the development of novel treatments for sarcomas of bone and of carcinomas metastatic to bone.Keywords
This publication has 46 references indexed in Scilit:
- Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcomaBMC Cancer, 2004
- Targeting of EWS/FLI‐1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitroJournal of Orthopaedic Research, 2004
- Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-β-Catenin PathwayCancer Research, 2004
- The predictive potential of molecular detection in the nonmetastatic Ewing family of tumorsCancer, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Expression of LDL receptor‐related protein 5 (LRP5) as a novel marker for disease progression in high‐grade osteosarcomaInternational Journal of Cancer, 2003
- The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instabilityProceedings of the National Academy of Sciences, 2003
- Metastasis to bone: causes, consequences and therapeutic opportunitiesNature Reviews Cancer, 2002
- EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.Journal of Clinical Oncology, 1998
- WNTs modulate cell fate and behavior during vertebrate developmentTrends in Genetics, 1997